HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors

被引:69
|
作者
Spence, RA
Anderson, KS
Johnson, KA
机构
[1] PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA
[2] YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06520 USA
关键词
D O I
10.1021/bi952058+
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The parameters governing the polymerization mechanism of reverse transcriptase containing the tyrosine to cysteine mutation at position 181 (Y181C) were determined using pre-steady-state techniques. The pathway for single nucleotide incorporation catalyzed by Y181C is similar to that determined for wild-type RT where a rate-limiting conformational change precedes fast chemistry and is followed by slow steady-state release of the primer/template. The Y181C mutant enzyme binds a 25/45-mer duplex DNA tightly with a K-d of 11 nM. However, the Y181C mutation weakens the nucleotide affinity 2-3-fold relative to the wild-type complex. We also determined the parameters governing the mechanism of nonnucleoside inhibitor resistance with Y181C. The K-d value of Nevirapine with the mutant E . DNA complex increased approximately 500-fold. The decreased affinity of Nevirapine for the mutant enzyme is a consequence of a faster inhibitor dissociation rate from the enzyme complex of Y181C relative to that of the wild-type. The E . DNA complex of Y181C may be saturated with Nevirapine, and the I . E . DNA complex is capable of a maximum incorporation rate of 0.1 s(-1) (a 10-fold faster rate than that of the wild-type I . E . DNA complex). The overall two-step binding of nucleotide to Y181C in the presence of Nevirapine remains unaffected.
引用
收藏
页码:1054 / 1063
页数:10
相关论文
共 50 条
  • [1] Mechanisms of HIV-1 drug resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors
    G. N. Nikolenko
    A. T. Kotelkin
    S. F. Oreshkova
    A. A. Ilyichev
    [J]. Molecular Biology, 2011, 45 : 93 - 109
  • [2] Mechanisms of HIV-1 drug resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors
    Nikolenko, G. N.
    Kotelkin, A. T.
    Oreshkova, S. F.
    Ilyichev, A. A.
    [J]. MOLECULAR BIOLOGY, 2011, 45 (01) : 93 - 109
  • [3] THE GENETIC AND FUNCTIONAL BASIS OF HIV-1 RESISTANCE TO NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS
    EMINI, EA
    BYRNES, VW
    CONDRA, JH
    SCHLEIF, WA
    SARDANA, VV
    [J]. ARCHIVES OF VIROLOGY, 1994, : 11 - 17
  • [4] Disubstituted uracils as novel nonnucleoside inhibitors of HIV-1 reverse transcriptase inhibitors
    Valuev-Elliston, V.
    Babkov, D.
    Paramonova, M.
    Ivanov, A.
    Kochetkov, S.
    [J]. FEBS JOURNAL, 2013, 280 : 370 - 370
  • [5] MECHANISM OF INHIBITION OF HIV-1 REVERSE-TRANSCRIPTASE BY NONNUCLEOSIDE INHIBITORS
    ESNOUF, R
    REN, JS
    ROSS, C
    JONES, Y
    STAMMERS, D
    STUART, D
    [J]. NATURE STRUCTURAL BIOLOGY, 1995, 2 (04): : 303 - 308
  • [6] MECHANISM OF INHIBITION OF HIV-1 REVERSE-TRANSCRIPTASE BY NONNUCLEOSIDE INHIBITORS
    SPENCE, RA
    KATI, WM
    ANDERSON, KS
    JOHNSON, KA
    [J]. SCIENCE, 1995, 267 (5200) : 988 - 993
  • [7] The role of nonnucleoside reverse transcriptase inhibitors for the treatment of HIV-1 infection
    Wang, Qian
    Zheng, Yong-Tang
    [J]. Chinese Pharmaceutical Journal, 2002, 37 (12) : 881 - 884
  • [8] The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors
    Sluis-Cremer, Nicolas
    [J]. VIRUSES-BASEL, 2014, 6 (08): : 2960 - 2973
  • [9] Novel diarylpyrimidine subtypes as HIV-1 nonnucleoside reverse transcriptase inhibitors with improved resistance profile
    Wang, Zhengqiang
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (03)
  • [10] Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase
    Barnard, John P.
    Huber, Kelly D.
    Sluis-Cremer, Nicolas
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (08)